Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

SH003, A Standardized Herbal Supplement, and NK Cell Cytotoxicity in Older Adults With Recurrent Upper Respiratory Infections: A Randomized, Double-Blind, Placebo-Controlled Trial.

Created on 15 Nov 2026

Authors

Chunhoo Cheon, Soobin Jang, Seong-Gyu Ko

Published in

Food science & nutrition. Volume 14. Issue 11. Pages e72585. Epub Nov 13, 2026.

Abstract

This study evaluated the immunomodulatory efficacy and safety of SH003-a standardized herbal extract derived from Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii-in adults with a mildly weakened immune system. In this single-center, randomized, double-blind, placebo-controlled trial, 120 adults (predominantly older women; mean age 61.4 years; 91.7% female) with a history of recurrent upper respiratory infections were randomly assigned in a 1:1 ratio to receive either SH003 (2 g/day) or a placebo for 8 weeks. The primary outcome was the change in natural killer cell cytotoxic activity from baseline to week 8. Secondary outcomes included serum cytokine levels, systemic inflammatory markers, stress, respiratory symptoms, and safety parameters. Efficacy analyses were adjusted for baseline covariates using analysis of covariance. After 8 weeks, the SH003 group demonstrated a statistically significant increase in NK cell cytotoxicity at an effector-to-target ratio of 1.25:1 compared to the placebo group in the per-protocol analysis (p = 0.044, ANCOVA-adjusted). However, this finding was not replicated in the full analysis set (p = 0.112) or intention-to-treat analysis (p = 0.131), indicating limited robustness. No significant between-group differences were observed for cytokine levels or respiratory symptom scores. Erythrocyte sedimentation rate was reduced in the SH003 group; this did not reach significance in the unadjusted comparison (p = 0.085) but became significant after ANCOVA adjustment (p = 0.045). No serious adverse events were reported during the trial. These findings are preliminary and exploratory; the per-protocol result at the 1.25:1 ratio should not be interpreted as confirmatory evidence of efficacy, and replication in an independent, adequately powered trial is required.

PMID:
43034374
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement